ACE2 and COVID-19: There is evidence of an increase in the expression of ACE2 in injured liver tissue, caused by a dysregulated immune response against SARS-CoV-2, ischemia or hypoxia during the clinical evolution of COVID-19, or by hepatotoxic drugs used during the treatment [10,81,82,97].